Although calcitonin declines do not always directly correlate with clinical responses, this response is noteworthy and highlights the potential for immunotherapy or sequential immunotherapy in metastatic or unresectable MTC. The gene discussed is CALCA; the disease is medullary thyroid gland carcinoma.